Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: APD356 Clear all
Completed No phase listed Observational Accepts healthy volunteers

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

NCT03552107
View directory record Official record
Conditions
Obesity, Weight Loss, Overweight
Interventions
Lorcaserin
Drug
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Lorcaserin in Obesity: Identification of CNS Targets Using fMRI

NCT02400359
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Lorcaserin HCl, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 3 Interventional Results available

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

NCT02932215
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
lorcaserin, Fitbit Charge HR
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Terminated Phase 1 Interventional

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

NCT03143543
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo, Group B2 Parallel Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

NCT00828724
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 3 Interventional Results available

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

NCT00395135
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin 10 mg BID, Matching Placebo BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake

NCT00829140
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Lorcaserin 10mg BID
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926
View directory record Official record
Conditions
Cannabis Use
Interventions
Lorcaserin, Placebo, Marijuana
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder

NCT03143855
View directory record Official record
Conditions
Opioid Abuse, Opioid Dependence, Opioid-Related Disorders, Opioid Use
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 20, 2026, 3:31 AM EDT
Terminated Phase 1 Interventional

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Ziprasidone, Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 3:31 AM EDT
Withdrawn Phase 1 Interventional

Rebalancing the Serotonergic System in Cocaine Dependence

NCT03266939
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Lorcaserin, Placebo Oral Tablet
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

NCT02129608
View directory record Official record
Conditions
Overweight, Obese
Interventions
LLLT, Lorcaserin
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00116740
View directory record Official record
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Not listed Phase 4 Interventional

Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study

NCT01962402
View directory record Official record
Conditions
Weight Gain
Interventions
lorcaserin, Intensive dietary counseling
Drug · Behavioral
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 20, 2026, 3:31 AM EDT
Completed No phase listed Observational Results available

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

NCT06090461
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31,889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 20, 2026, 3:31 AM EDT
Terminated Early Phase 1 Interventional Results available

Lorcaserin for Cannabis Use Disorder

NCT03637842
View directory record Official record
Conditions
Cannabis Use Disorder
Interventions
Lorcaserin, Placebo oral capsule
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

NCT02388568
View directory record Official record
Conditions
Obesity
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 20, 2026, 3:31 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Mechanisms of Lorcaserin for Smoking Cessation

NCT04396834
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking Cessation
Interventions
Lorcaserin Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APD356 in the Treatment of Obesity

NCT00104507
View directory record Official record
Conditions
Obesity
Interventions
APD356
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 20, 2026, 3:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

NCT02022956
View directory record Official record
Conditions
Pharmacokinetics in Obese Adolescents
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 3:31 AM EDT